Parkinson's disease and the bones

Swiss Medical Weekly

Volumn 141, Issue FEBRUARY, 2011, Pages

  Gnädinger, Markus ^a   Mellinghoff, Hans Ulrich ^b   Kaelin Lang, Alain ^c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Accidental falls; Bone density; Bone fractures; Homocysteine; Levodopa; Osteoporosis; Parkinson's disease; Vitamin D

Indexed keywords

ADRENALIN; ALENDRONIC ACID; BENSERAZIDE; CALCITRIOL; CALCIUM ION; CARBIDOPA; CATECHOL METHYLTRANSFERASE; COLECALCIFEROL; CREATININE; CYANOCOBALAMIN; DEOXYPYRIDINOLINE; DOPAMINE 2 RECEPTOR; FARNOQUINONE; GROWTH HORMONE; HOMOCYSTEINE; LEVODOPA; OSTEOCALCIN; PHYTOMENADIONE; RISEDRONIC ACID; S ADENOSYLHOMOCYSTEINE; S ADENOSYLMETHIONINE; SOMATOMEDIN C; ANTIPARKINSON AGENT; VITAMIN D;

ACCIDENT PREVENTION; ADRENAL CORTEX; ALZHEIMER DISEASE; AMINO ACID BLOOD LEVEL; ASPIRATION PNEUMONIA; AUTONOMIC DYSFUNCTION; BODY EQUILIBRIUM; BONE DEFECT; BONE DENSITY; BONE DISEASE; BONE MASS; BONE METABOLISM; BONE TURNOVER; BRADYKINESIA; BRAIN DEPTH STIMULATION; CAUSE OF DEATH; CLIMACTERIUM; CLINICAL EXAMINATION; CORTICAL BONE; CREATININE URINE LEVEL; DEMENTIA; DISEASE COURSE; DISEASE SEVERITY; DIURESIS; DRUG METABOLISM; DYSPHAGIA; EMBASE; ENDOCRINE FUNCTION TEST; FALL RISK; FALL RISK ASSESSMENT; FALLING; FOLLOW UP; FRACTURE; GAIT DISORDER; GENE DELETION; GLOMERULUS FILTRATION; HIGH RISK PATIENT; HIP FRACTURE; HORMONE RELEASE; HUMAN; HYPERHOMOCYSTEINEMIA; IMMOBILIZATION; MEDLINE; MORTALITY; MUSCLE RIGIDITY; NATRIURESIS; NONHUMAN; NUTRITIONAL DEFICIENCY; OSTEOLYSIS; OSTEOPOROSIS; PARKINSON DISEASE; PHYSIOTHERAPY; PNEUMONIA; PROTEIN SYNTHESIS INHIBITION; PROVOCATION TEST; REFLEX DISORDER; REVIEW; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; STABILOGRAPHY; SUN EXPOSURE; UNSTEADINESS; URINARY EXCRETION; URINE INCONTINENCE; VITAMIN BLOOD LEVEL; WEIGHT REDUCTION; BONE; DRUG EFFECT; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK ASSESSMENT; STATISTICS;

ACCIDENTAL FALLS; ANTIPARKINSON AGENTS; BONE AND BONES; BONE DENSITY; FRACTURES, BONE; HUMANS; LEVODOPA; OSTEOPOROSIS; PARKINSON DISEASE; RISK ASSESSMENT; VITAMIN D;

EID: 79955872388     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: 10.4414/smw.2011.13154     Document Type: Review

References (108)

1. Parkinson J. An essay on the shaking palsy. London, Wittingham and Rowland, 1817; chapt. 1.
2. Bennet DA, Beckett LA, Murray AM, et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med. 1996;334:71-6. (Pubitemid 26017932)
3. Follet KA, Weaver FM, Stern M, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. NEJM. 2010;362:2077-91.
4. Katzenschlager R, Head J, Schrag A, et al. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology. 2008;71:474-80.
5. Vaserman N, et al. Arthropatic appearances in Parkinson's disease. Revue de Gériatrie 2001;26:2(95-104).
6. Bloem BR, Grimbergen YA, Cramer M, et al. Prospective assessment of falls in Parkinson's disease. J Neurol. 2001;248:950-8. (Pubitemid 36124720)
7. Camicioli R, Majumdar SR. Relationship between mild cognitive impairment and falls in older people with and without Parkinson's disease: 1-year prospective cohort study. Gait&Posture. 2010;87-91.
8. Ashburn A, Fazakarley L, Ballinger C, et al. A randomized controlled trial of a home based exercise programme to reduce the risk of falling among people with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2007;78:678-84. (Pubitemid 46998834)
9. Gray P, Hildebrand K. Fall risk factors in Parkinson's disease. J Neurosci Nurs. 2000;32:222-8.
10. Koller WC, Glatt S, Vetere-Overfield B, et al. Falls and Parkinson's disease. Clin Neuropharmacol. 1989;12:98-105. (Pubitemid 19088635)
11. Matinolli M, Korpelainen JT, Korpelainen R, et al. Mobility and balance in Parkinson's disease: a population-based study. Eur J Neurol. 2009;16:105-11.
12. Sadowski CA, Jones CA, Gordon B. Knowledge of risk factors for falling reported by patients with Parkinson's disease. J Neurosci Nursing. 2007;39:336-41.
13. Balash Y, Peretz Ch, Leibovich G, et al. Falls in outpatients with Parkinson's disease. J Neurol. 2005;252:1310-5.
14. Deandra S, Lucenteforte E, Bravi F, et al. Risk factors for falls in community-dwelling older people. A systematic review and meta-analysis. Epidemiology. 2010;21:658-68.
15. Wood BH, Bilclough JA, Bowron A, et al. Incidence and prediction of falls in Parkinson's disease: a prospective multidisciplinary study. J Neurol Neurosurg Psychiatry. 2002;72:721-5. (Pubitemid 34557012)
16. Williams DR, Watt HC, Lees AJ. Predictors of falls and fractures in bradykinetic rigid syndromes: a retrospective study. J Neurol Neurosurg Pschiatry. 2006;77:468-73.
17. Kerr GK, Worringham CJ, Cole MH, et al. Predictors of future falls in Parkinson disease. Neurology. 2010;75:116-24.
18. Dibble LE, Lange M. Predicting falls in individuals with Parkinson disease: a reconsideration of clinical balance measures. J Neurol Phys Ther. 2006;30:60-7.
19. Chien SL, Lin SZ, Liang CC, et al. The efficacy of quantitative gait analysis by the GAITRite system in evaluation of parkinsonian bradykinesia. Parkinsonism Rel Dis. 2006;12:438-42.
20. Frenklach A, Louie S, Miiler Koop M, et al. Excessive postural sway and the risk of falls at different stages of Parkinson's disease. Mov Dis. 2009;24:377-85.
21. Morris ME, Marin CL, Schenkman ML. Striding out with Parkinson Disease: Evidence-based physical therapy for gait disorders. Phys Ther. 2010;90:280-8.
22. Rochester L, Burn DJ, Woods G, et al. Does auditory rhythmical cueing improve gait in people with Parkinson's disease and cognitive impairment? A feasibility study. Mov Dis. 2009;24:839-45.
23. Ashburn A, Fazakarley, Ballinger C, et al. A randomized controlled trial of a home based exercise programme to reduce the risk of falling among people with Parkinson's disease. J Neurol Neurosurg Psych. 2007;78:678-84. (Pubitemid 46998834)
24. Allen NE, Canning CG, Sherrington C, et al. The effects of an exercise program on fall risk factors in people with Parkinson's disease: a randomized controlled trial. Mov Dis. 2010;25:1217-25.
25. Buracchio T, Arvanitakis Z. Parkinsonian signs and incident falls in older persons without Parkinson's disease (Letter to the editor). J Am Geriatr Soc. 2010;58:205-6.
26. Klawans HL, Topel JL. Parkinsonism as a falling sickness. JAMA. 1974;230:1555-7.
27. Chung KA, Lobb BM, Nutt JG, et al. Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology. 2010;75:1263-9.
28. Moro E, Hamani C Poon YY, et al. Unilateral pedunculopontine stimulation improves falls in Parkinson's disease. Brain. 2010;133:215-24.
29. Grimbergen YAM, Munneke M, Bloem BR, et al. Falls in Parkinson's disease. Curr Opin Neurol. 2004;17:405-15. (Pubitemid 39071416)
30. Johnell O, Melton LJ, Atkinson EJ, et al. Fracture risk in patients with parkinsonism: a population-based study in Olmsted county, Minnesota. Age Ageing. 1992;21:32-8.
31. Genever RW, Downes TW, Medcalf P. Fracture rates in Parkinson's disease compared with age- and gender-machted controls: a retrospective cohort study. Age Ageing. 2005;34:21-4. (Pubitemid 40109663)
32. Schneider JL, Fink HA, Ewing SK, et al. The association of Parkinson's disease with bone mineral density and fracture in older women. Osteoporosis Int. 2008;19:1093-7.
33. Fink HA, Kuskowski MA, Taylor BC, et al. Association of Parkinson's disease with accelerated bone loss, fractures and mortality in older men: the osteoporotic fractures in men (MrOs) study. Osteoporosis Int. 2008;19:1277-82.
34. Grisso JA, Kelsey JL, Storm BL, et al. Risk factors for falls as a cause of hip fracture in women. N Engl J Med. 1991;324:1326-31.
35. Taylor BC, Schreiner PJ, Stone KL, et al. Long-term prediction of incident hip fracture risk in elderly white women: study of osteoporotic fractures. J Am Geriatr Soc. 2004;52:1479-86. (Pubitemid 39209595)
36. Nguyen T, Sambrook P, Kelly P, et al. Prediction of osteoporotic fractures by postural instability and bone density. BMJ. 1993;307:1111-5. (Pubitemid 23313207)
37. Vestergaard P, Rejmark L, Mosekilde L. Fracure risk associatred with parkinsonism and anti-parkinson drugs. Calcif Tissue Int. 2007;81:153-61. (Pubitemid 47373359)
38. The North American Menopause Society: Management of osteoporosis in postmenopausal women: 2010 position statement. Menopause. 2010;17:25-54.
39. Diem-Zangerl A, Seppi K, Wenning GK, et al. Mortality in Parkinson's disease: a 20-year follow-up study. Mov Dis. 2009;24:819-25.
40. Berger K, Breteler MMB, Helmer C, et al. Prognosis with Parkinson's disease in Europe: a coccaborative study of population-based cohorts. Neurology. 2000;54:S24-7.
41. Herlofson K, Lie AS, Arsland D, et al. Mortality and Parkinson's disease. A community based study. Neurology. 2004;62:937-42.
42. Hely MA, Morris JGL, Reid WGJ, et al. Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Dis. 2005;20:190-9. (Pubitemid 40361122)
43. Hobson P, Meara J, Ishihara-Paul L. The estimated life expectancy in a community cohort of Parkinson's disease patients with and without dementia, compared with the UK population. J Neurol Neurosurg Psychiatry. 2010;81:193-8.
44. Rajput AHR, Uitti RJ, Rajput A, et al. Mortality in Parkinson's disease (Letter). Mov Dis. 2010;25:507-8.
45. Mylne AQN, Griffiths C, Rooney C, et al. Trends in Parkinson's disease related mortality in England and Wales, 1993-2006. Eur J Neurol. 2009;16:1010-6.
46. Fall PA, Saleh A, Fredrickson M, et al. Survival time, mortality, and cause of death in elderly patients with Parkinson's disease: a 9-year follow-up. Mov Dis. 2003;18:1312-6. (Pubitemid 38263316)
47. D'Amelio M, Ragonese P, Morgante L, et al. Lont-erm survival of Parkinson's disease. A population-based study. J Neurol. 2006;253:33-7. (Pubitemid 43157385)
48. Pennington S, Snell K, Lee M, et al. The cause of death in idiopathic Parkinson's disease. Park Rel Dis. 2010;16:434-7.
49. Ebmeier KP, Calder SA, Crawford JR, et al. Mortality and causes of death in idiopathic Parkinson's disease: results from the Aberdeen whole population study. Scot Med J. 1990;35:173-5.
50. Vinogradova Y, Hippisley-Cox J, Coupland C. Identification of new risk factors for pneumonie: population-based case-control study. Br J Gen Pract. 2009; DOI: 10.3399/bjgp09X472629.
51. Hristova DR. Standardized mortality ratio and seasonal fluctuations of mortality in Parkinson's disease. Folia Mecica. 2009;51:40-5.
52. Kao CH, Chen CC, Wang SJ, et al. Bone mineral density in patients with Parkinson's disease measured by dual photon absorptiometry. Nucl Med Comm. 1994;15:173-7. (Pubitemid 24104354)
53. Taggart H, Crawford V. Reduced bone density of the hip in elderly patients with Parkinson's disease. Age Ageing. 1995;24:326-8.
54. Lorefält B, Toss G, Granérus AK, et al. Bone mass in elderly patients with Parkinson's disease. Acta Neurol Scand. 2007;116:248-54.
55. Abou-Raya S, Helmii M, Abou-Raya A. Bone and mineral metabolism in older adults with Parkinson's disease. Age Ageing. 2009;38:675-80.
56. Bezza A, Ouzzif Z, Naji H, et al. Prevalence and risk factors of osteoporosis in patients with Parkinson's disease. Rheumatol Int. 2008;28:1205-9.
57. Kamanli A, Ardicoglu O, Ozgocmen S, et al. Bone mineral density in patients with Parkinson's disease. Aging Clin Exp Res. 2008;20:277-9.
58. Lam K, Li M, Mok V, et al. A case control study on bone mineral density in Chinese patients with Parkinson's disease. Park Rel Dis. 2010;16:471-4.
59. Sato Y, Manabe S, Kuno H, et al. Amelioration of osteopenia and hypovitaminosis D by 1α-hydroxyvitamin D3 in elderly patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 1999;66:64-8. (Pubitemid 29101490)
60. Sato Y, Honda Y, Kaji M, et al. Amelioration of osteoporosis by menatetrenone in elderly female Parkinson's disease patients with vitamin D deficiency. Bone. 2002;31:114-8. (Pubitemid 34754436)
61. Ishizaki F, Harada T, Katayama S, et al. Relationship between osteopenia and clinical characteristics of Parkinson's disease. Movement Disorders. 1993;8:507-11. (Pubitemid 23291207)
62. Sato Y, Iwamoto J, Kanoko T, et al. Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial. Movement disorders. 2006;21:924-9. (Pubitemid 44184591)
63. Sato Y, Honda Y, Iwamoto J. Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson's disease. Neurology. 2007;68:911-5. (Pubitemid 46568502)
64. Evatt ML, DeLong MR, Khazai N, et al. Prevalence of vitamin D insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol. 2008;65:1348-52.
65. Sato Y, Kikuyama M, Oizumi K. High prevalence of vitamin D deficiency and reduced bone mass in Parkinson's disease. Neurology. 1997;49:1273-8. (Pubitemid 27495628)
66. Sato Y, Iwamoto J, Honda Y. Amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in Parkinson's disease. Parkinson Rel Dis 2010; DOI; 10.1016/j.parkreldis.2010.10.008.
67. Rico H, Vazquez A, Cabranes JA, et al. Long-term influence of levodopa on bone mass and growth hormone in postmenopausal women with Parkinson's disease. Clin Neuropharmacol. 1987;10:87-91. (Pubitemid 17005661)
68. Arbouw MEL, Movig KLL, von Staa TP, et al. Dopaminergic drugs and the risk of hip or femur fracture: a population-based case-control study. Osteoporosis Int 2010; DOI 10.1007/s00198-010-1455-3.
69. Inglis GC, Kenyon CJ. Effects of long-term infusions of dopa and carbidopa on renin and steroid secretion in the rat. Endocrinology. 1992;131:2941-5.
70. Luippold G, Küster E, Joos TO, et al. Dopamine D3 receptor activation modulates renal function in anesthetized rats. Naunyn-Schmiedeberg's Arch Pharmacol. 1998;358:690-3. (Pubitemid 28563775)
71. Luippold G, Mühlbauer B. Dopamine D2 receptors mediate glomerular hyperfiltration due to amino acids. J Pharamacol Exp Ther. 1998;286:1248-52. (Pubitemid 29135536)
72. Bliziotes M, McLoughlin S, Gunness M, et al. Bone histomorphometric and biomechanical abnormalities in mice homozygous for deletion of the dopamine transporter gene. Bone. 2000;26:15-9.
73. Kytömäki O, Nousiainen R, Pekkarinen A, et al. Plasma growth hormone and insulin response to levodopa and amantadine. J Neural Transmission. 1973;34:145-51.
74. Rhee EJ, Oh KW, Lee WY, et al. Age, body mass index, current smoking history, and serum insulin-like growth factor-I levels associated with bone mineral density in middle-aged Korean men. J Bone Miner Metab. 2004;22:392-8.
75. Diebold J, Bätge B, Stein H, et al. Osteoporosis in longstanding acromegaly: characteristic changes of vertebral trabecular architecture and bone matrix composition. Virchows Archiv A Pathol Anat. 1991;419:209-15.
76. Bellomo G, Santambrogio L, Fiacconi M, et al. Plasma profiles of adrenocorticotropic hormone, cortisol, growth hormone and prolactin in patients with untreated Parkinson's disease. J Neurol. 1991;238:19-22.
77. O'Suilleabhain PE, Bottiglieri T, Dewey RB, et al. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease. Mov Dis. 2004;19:1403-8. (Pubitemid 40109481)
78. Sato Y, Iwamoto J, Kanoko T, et al. Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson's disease. Am J Med. 2005;118:1250-55. (Pubitemid 41566526)
79. Lee SH, Kim MJ, Kim BJ, et al. Hyperhomocysteinemia due to levodopa treatment as a risk factor for osteoporosis in patients with Parkinson's disease. Calcif Tissue Int. 2010;86:132-41.
80. vanMeurs JBJ, Dhonukshe-Rutten RAM, Pluijm SMF, et al. Homocysteine levels and the risk of osteoporotic fracture. NEJM. 2004;350:2033-41.
81. Lee SH, Kim MJ, Kim BJ, et al. Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson's disease. Mov Dis. 2010;25:332-40.
82. Sato Y, Honda Y, Iwamoto J, et al. Effect of folate and mecobalamin on hip fractures in patients with stroke. JAMA. 2005;293:1082-8. (Pubitemid 40300282)
83. Tanaka C, Tanaka S, Itokawa Y, et al. Skeletal changed induced by dopa decarboxylase inhibitor in rats. Japan J Pharmacol. 1973;23:123-5.
84. Schärer K. Special developmental derangements of the rat skeleton after administration of DL-Serine-(2,3,4-trihydroxybenzyl) hydrazide] (German). Beitr Path. 1974;152:127-50.
85. Savica R, Rocca WA, Ahlskog JE. When does Parkinson disease start? Arch Neurol. 2010;67:798-801.
86. Karachi C, Grabli D, Bernard FA, et al. Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease. J Clin Invest. 2010;120:2745-54.
87. Zaidel A, Arkadir D, Israel Z, et al. Akineto-rigid vs. tremor syndromes in parkinsonism. Curr Opin Neurol. 2009;22:387-93.
88. Mak MKY, Pang MYC. Fear of falling is independently associated with recurrent falls in patients with Parkinson's disease: a 1-year prospective study. J Neurol. 2009;256:1689-95.
89. Tinetti ME, Kumar C. The patient who falls / "It's always a trade-off". JAMA. 2010;303(3):258-66.
90. The American Geriatrics Society: Clinical practice Guideline: Prevention of falls in older persons. http://www.americangeriatrics.org/health-care- professionals/clinical-practice/clinical-guidelines-recommendations/2010/
91. Gillespie LD, Robertson MC, Gillespie WJ, et al. Interventions for preventing falls in older people living in the community. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD007146. DOI: 10.1002/14651858. CD007146.pub2.
92. Petroni MI, Albani G, Bicchiega V, et al. Body composition in advanced-stage Parkinson's disease: Acta Diabetol. 2003;40:S187-90.
93. Invernizzi M, Carda S, Sguazzini Visconti G, et al. Osteoporosis in Parkinson's disease. Parkinsonism Rel Dis. 2009;15:339-46.
94. Knekt P, Kilkkinen A, Rissanen H, et al. Serum Vitamin D and the risk of Parkinson disease. Arch Neurol. 2010;67:808-11.
95. Sato Y, Oizumi K, Kuno H, et al. Effect of immobilization upon renal synthesis of 1,25-dihydroxyvitamin D in disabled elderly stroke patients. Bone. 1999;24:271-5. (Pubitemid 29094572)
96. Blumenkrantz N, Asboe-Hansen G. Inhibitory effect of L-dopa on collagen biosynthsis. Acta Med Scand. 1974;195:37-8.
97. Lubec B, Fang-Kircher S, Lubec T, et al. Evidence for McKusick's hypothesis of deficient collagen cross-linking in patients with homocysteinuria. Biochimica et Biophysica Acta. 1996;1315:159-62. (Pubitemid 26128323)
98. Zoccolella S, dell'Aquila C, Abruzzese G, et al. Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia.
99. Huang T, Yuan G, Zhang Z, et al. Cardivascular pathogenesis in hyperhomocysteinemia. Asia Pac J Clin Nutr. 2008;17:8-16.
100. Marti-Carvajal AJ, Sola I, Lathyris D, et al. Homocysteine lowering interventions for preventing cardiovascular events. Cochrane Database of Systematic Reviews 2009; Issue 4 Art. No.: CD006612. DOI: 10.1002/14651858. CD006612.pub2.
101. Zoccolella S, Lamberti P, Armenise E, et al. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications. Parkinsonism and Related Disorders. 2005;11:131-3. (Pubitemid 40279156)
102. Lamberti P, Zoccolella S, Iliceto G, et al. Effects of levodopa and COMT-inhibitors on plasma homocysteine in Parkinsons' disease patients. Mov Dis. 2005;20:69-72. (Pubitemid 40277507)
103. Farhat G, Yamout B, Mikati MA, et al. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology. 2002;58:1348-53. (Pubitemid 34507160)
104. Fiore CE, Tamburino C, Foti R, et al. Reduced axial bone mineral content in patients taking an oral anticoagulant. South Med J. 1990;83:538-42. (Pubitemid 20174513)
105. Grey A, Bolland M, Gamble G, et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab. 2007;92:1305-10. (Pubitemid 46556402)
106. Diem SJ, Blackwell TL, Stone KL, et al. Use of antidepressants and rates of hip bone loss in older women. Arch Intern Med. 2007;167:1240-5.
107. Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947-53. (Pubitemid 46021498)
108. Mukherjee D. Nonsteroidal anti-inflammatory drugs and the heart: what is the danger? Congestive heart failure. 2008;14:5-82.